Hepatitis Forums
Fatty Liver Disease Main Forums => Nonalcoholic Steatohepatitis (NASH) => Topic started by: Hep Editors on December 09, 2020, 12:38:02 pm
-
Genfit announced this week that it will stop the development of its non-alcoholic steatohepatitis (NASH) drug candidate elafibranor, which was in the running to become the first NASH therapy approved by the Food and Drug Administration (FDA).
NASH and its less severe form, non-alcoholic fatty liver disease (NAFLD), are responsible for a growing proportion of advanced liver disease. The buildup of fat in the liver triggers inflammation, which over time can lead to liver fibrosis, cirrhosis and liver cancer. With no effective medical therapies currently approved—and with several candidates recently missing the mark—management relies on lifestyle changes such as weight loss and exercise.
Read more...
https://www.hepmag.com/article/company-halts-leading-nash-drug-another-shows-promise